Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Aprocitentan on Oral Contraceptives PK
NCT06799884Phase 1Completed
- Sponsor
- Idorsia
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aprocitentan in resistant hypertension (RH), sponsored by Idorsia. Primary endpoints: Maximum plasma concentration of ethinyl estradiol/levonorgestrel at Day 14, Time to maximum plasma concentration of ethinyl estradiol/levonorgestrel at Day 14 and 4 more. Started Jan 2025; status: completed.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT06799884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799884.